智通财经网·2025-12-23 00:12Core Viewpoint - Fosun Pharma is acquiring a 51% stake in Green Valley Pharmaceutical through a combination of stock transfer and capital subscription, with a total investment of 1.269 billion yuan, structured to manage clinical and investment risks effectively [1] Group 1: Acquisition Details - The acquisition involves a phased payment structure, with an initial payment of 635 million yuan at the time of closing and the remaining 634 million yuan to be paid within three years based on the company's subsequent R&D progress [1] - The founder-controlled entity of the target company will pledge 10% of its shares post-acquisition to provide collateral against potential risks [1] Group 2: Clinical Development Progress - Fosun Pharma is revising the post-marketing confirmatory clinical trial protocol for its Alzheimer's drug, extending the double-blind treatment period from 36 weeks to 48 weeks and increasing the sample size from 1,312 to 1,950 participants [2] - As of December 15, 2025, 580 participants have been enrolled in the clinical study, with full enrollment expected by the end of 2027 and data readout anticipated in early 2029 [2] Group 3: Strategic Focus - Fosun Pharma is enhancing its product portfolio in the field of neurodegenerative diseases, having developed a collaborative innovation model that includes both drugs and devices [3] - The acquisition is part of the company's strategy to address unmet clinical needs in this therapeutic area and to further enrich its pipeline of innovative products [3]